News

Austin, Texas-based International Biophysics Corporation, maker of AffloVest — a completely self-contained, battery operated, portable high-frequency chest wall oscillation (HFCWO) device for bringing critical therapy to people struggling with cystic fibrosis (CF), bronchiectasis, and other respiratory diseases — is joining several major U.S.

Hepatopulmonary syndrome (HPS), a liver-induced lung disorder, may be underdiagnosed in at-risk patients with cystic fibrosis (CF), according to a study titled “Hepatopulmonary Syndrome in Patients With Cystic Fibrosis and Liver Disease,” published in the journal Chest. Cystic fibrosis-associated liver disease (CFLD) is the third cause of mortality among…

XENiOS, a privately held medical device company specializing in minimally invasive lung-and-heart assistance, recently announced it has invested $2.6 million in  XOR-Labs Toronto, a spin-off of Toronto General Hospital at University Health Network (UHN) that is working to make more donor lungs available to patients needing transplants because of injuries…

A new study suggests a method for correcting and improving stem cells derived from people with cystic fibrosis (CF), one that could lead to new ways of treating CF using a patient’s own cells. The report, titled “Robust method for TALEN-edited correction of pF508del in patient-specific induced pluripotent stem cells,“ appeared…

Nivalis Therapeutics, Inc., recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead investigational drug, N91115, a stabilizer of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, as a potential treatment for patients with cystic fibrosis (CF). The drug is now being evaluated in…

Galapagos NV announced the start of its SAPHIRA Phase 2 exploratory study with the first dosing of GLPG1837 in a cystic fibrosis (CF) patient. Topline results are expected in late 2016. CF is triggered by a mutation in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein, resulting in abnormal…

Collaborative research between Eindhoven University of Technology (Netherlands), McGill University (Canada), and the University of Duisburg-Essen (Germany) has identified a promising approach that could lead to the development of an efficient treatment for cystic fibrosis (CF). The paper, “Characterization and small-molecule stabilization of the multisite tandem binding between 14-3-3…

Rhinovirus infections in children with cystic fibrosis (CF) are linked to a lack of improvement in lung function after treatment for pulmonary exacerbations caused by the infection, a recent study reported. The study,“Rhinovirus-associated pulmonary exacerbations show a lack of FEV1 improvement in children with cystic fibrosis,“ analyzed 18 children who were…

A study comparing two continuous treatment regimens of tobramycin inhalation (Tobi) for Pseudomonas aeruginosa infection in patients with cystic fibrosis (CF) found that administration of both once a day and twice daily treatment was safe and well-tolerated. The study, titled “Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation…

Researchers identified a novel, rare mutation causing cystic fibrosis (CF) in a pediatric African-American patient. The mutation, however, was found to be responsive to the CFTR corrector VX-809, therefore identifying potential personalized therapeutics. The study, “c.3623G > A mutation encodes a CFTR protein with impaired channel function,” was published…